Understanding how chemotherapy changes ovarian cancer cells
Chemo-mediated transcriptional reprogramming in ovarian cancer
This study is looking at why high-grade serous carcinoma, a tough type of ovarian cancer, stops responding to chemotherapy, and it aims to find ways to make those resistant cancer cells easier to treat again, which could help patients get better options for their treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10919180 on NIH RePORTER |
What this research studies
This research investigates how high-grade serous carcinoma, the most aggressive form of ovarian cancer, becomes resistant to chemotherapy. It focuses on the non-genetic mechanisms that lead to this resistance, particularly through changes in the cell's transcriptional programming. By using advanced techniques like CRISPR and genomic mapping, the researchers aim to identify specific factors that can help revert resistant cancer cells back to a more treatable state. This approach could lead to new strategies for overcoming chemotherapy resistance in patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with high-grade serous carcinoma who have experienced a relapse after initial chemotherapy treatment.
Not a fit: Patients with early-stage ovarian cancer who have not yet undergone chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new treatment options for patients with chemotherapy-resistant ovarian cancer.
How similar studies have performed: Other research has shown promise in using transcriptional reprogramming to address chemotherapy resistance, suggesting that this approach could be effective.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Adli, Mazhar — Northwestern University at Chicago
- Study coordinator: Adli, Mazhar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.